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Abstract
The hydrolysis in lysosomes of GM2 ganglioside to GM3 ganglioside requires the correct synthesis, intracellular assembly
and transport of three separate gene products; i.e., the alpha and beta subunits of heterodimeric beta-hexosaminidase A,
E.C. # 3.2.1.52 (encoded by the HEXA and HEXB genes, respectively), and the GM2-activator protein (GM2AP, encoded by
the GM2A gene). Mutations in any one of these genes can result in one of three neurodegenerative diseases collectively
known as GM2 gangliosidosis (HEXA, Tay-Sachs disease, MIM # 272800; HEXB, Sandhoff disease, MIM # 268800; and GM2A,
AB-variant form, MIM # 272750). Elements of both of the hexosaminidase A subunits are needed to productively interact
with the GM2 ganglioside-GM2AP complex in the lysosome. Some of these elements have been predicted from the crystal
structures of hexosaminidase and the activator. Recently a hybrid of the two subunits has been constructed and reported to
be capable of forming homodimers that can perform this reaction in vivo, which could greatly simplify vector-mediated
gene transfer approaches for Tay-Sachs or Sandhoff diseases. A cDNA encoding a hybrid hexosaminidase subunit capable of
dimerizing and hydrolyzing GM2 ganglioside could be incorporated into a single vector, whereas packaging both subunits
of hexosaminidase A into vectors, such as adeno-associated virus, would be impractical due to size constraints. In this report
we examine the previously published hybrid construct (H1) and a new more extensive hybrid (H2), with our documented in
cellulo (live cell- based) assay utilizing a fluorescent GM2 ganglioside derivative. Unfortunately when Tay-Sachs cells were
transfected with either the H1 or H2 hybrid construct and then were fed the GM2 derivative, no significant increase in its
turnover was detected. In vitro assays with the isolated H1 or H2 homodimers confirmed that neither was capable of human
GM2AP-dependent hydrolysis of GM2 ganglioside.
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Introduction
There are two major lysosomal beta-hexosaminidase (Hex)
isozymes in the normal human tissue; i.e., the highly stable Hex
B, a homodimer of beta subunits (encoded by the HEXB gene)
and the less stable Hex A, a heterodimer composed of beta and
alpha (encoded by the HEXA gene) subunits. These genes are
evolutionarily related with the primary structures of the two
subunits they encode being ,60% identical. Whereas Hex B
and Hex A share many of the same natural substrates, only
Hex A can hydrolyze the non-reducing terminal, beta-linked, N-
acetyl galactosamine residue from the acidic glycolipid GM2
ganglioside (GM2) to produce GM3 ganglioside. Because the
hydrophobic GM2 normally resides in a membranous environ-
ment, Hex A is sterically hindered from efficiently binding it
in vivo. This problem is overcome by the presence of a small
lysosomal glycolipid transport protein, the GM2-activator
protein (GM2AP). The GM2AP extracts a molecule of GM2
from the lysosomal membrane and then the complex specifically
binds to soluble Hex A, forming the active quaternary structure.
A deficiency of either of the two Hex A subunits or the
GM2AP, due to a mutation in their respective genes, can lead
to the accumulation of GM2 in the lysosomes of primarily
neuronal cells, where the synthesis of the more complex
gangliosides is the highest. This storage leads to neuronal cell
death and one of three similar neurodegenerative diseases
collectively known as GM2 gangliosidosis. These diseases are
Tay-Sachs disease (TSD), alpha subunit deficiencies, Sandhoff
disease (SD), beta subunit deficiencies and the rare AB-variant
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form, GM2AP deficiencies. Because of the complexity of
assaying Hex activity with its natural substrate (the GM2-
GM2AP complex), simple fluorescent artificial substrates were
introduced that are hydrolyzed by Hex in a GM2AP-
independent manner. The oldest of these is neutral 4-
methylumbelliferyl-2-acetamido-2-beta-D- glucopyranoside
(MUG). However, when MUG is used to assay total Hex
activity in TSD cells, nearly normal enzyme levels are obtained,
because of increased levels of Hex B. A newer, more specific,
negatively charged version of MUG, 4-methylumbelliferyl-2-
acetamido-2-deoxy-beta-D-glucopyranoside-6-sulfate (MUGS)
was developed that is only poorly bound and hydrolyzed by
Hex B and can thus be used directly to diagnose TSD. In SD
both Hex A and B are deficient, but a small amount of Hex
activity (,2% of normal, as measured by MUG) persists due to
the inefficient formation of an unstable acidic isozyme, Hex S,
an alpha homodimer (alpha monomers are cleared by the
endoplasmic reticulum associated degradation system). While
human Hex S, like Hex B, is unable to interact with the GM2-
GM2AP complex, it can hydrolyze MUGS more efficiently than
Hex A. The ,MUG/MUGS ratios of the Hex isozymes are;
Hex A, 4/1; Hex B, 300/1; and Hex S, 1/1 (reviewed in [1]).
The crystal structure of Hex B [2,3], Hex A [4] and the
GM2AP [5] have been elucidated and a model for the active
quaternary structure, i.e. Hex A-GM2AP-GM2 complex, gener-
ated [2]. Several important observations were made from these
structures. Firstly, whereas each subunit has an active site, residues
from the neighboring subunit in the dimer are needed to stabilize
and complete the site. Thus monomeric subunits are not active.
Secondly, the structures confirm previous findings that the ability
of the alpha active site to efficiently hydrolyze negatively charged
substrates, e.g. MUGS and GM2, comes primarily from two
aligned amino acid differences in the subunits, i.e. alpha-N423-
R424 and beta-D452-L453. The basic R424 residue in alpha can
ion pair with either the 6-sulfate of MUGS [6] or the sialic acid of
GM2 [7], whereas the acidic D452 residue in beta repels these
same moieties. Finally several areas in both subunits were
identified as being potentially important in facilitating the
formation of the active quaternary structure. These included two
loop structures in alpha, GSEP283 and IPV398. In beta the
former alpha-loop sequence aligns with RQNK315, which is
removed proteolytically in the lysosome, producing the mature 29
and 24 kDa beta chains [8,9], and the latter loop is not encoded
by the beta mRNA [10]. The importance of the alpha- GESP283,
but not the IPV loop in GM2AP-GM2 binding has been
confirmed experimentally [11].
Recently Matsuoka et al. used the above information to
construct a human hybrid Hex subunit (Table 1) that retained
the high stability of the beta subunit while reportedly being able to
bind the GM2AP and efficiently hydrolyze GM2 (and MUGS).
They suggested that this hybrid Hex could be used for enzyme
replacement therapy [12].
Another approach to treating TSD and SD is gene therapy.
Proof-of-concept gene transfer experiments have demonstrated
the potential for long-term therapeutic rescue of GM2
ganglioside accumulations and improvement of disease symp-
toms in mouse models for SD or TSD [13–15]. Adeno-
associated virus (AAV) vectors have been utilized in over 75
gene transfer clinical trials because of their excellent safety
record, relatively low immunogenicity, and ability to confer
long-term expression of the delivered transgene (reviewed in
[16]). Recently, widespread central nervous system (CNS) gene
transfer has been demonstrated in feline, porcine, and non-
human primate animal models [17–21], suggesting the possibil-
ity for a translatable gene transfer approach for disorders such
as Tay-Sachs disease using AAV vectors. A major limitation for
AAV is its packaging capacity, which is approximately 4.5 kb of
foreign DNA for traditional single-strand AAV, and approxi-
mately 2.1 kb for the more efficient self-complementary AAV
[16]. The coding DNA sequence for the alpha-subunit of Hex
A is 1613 bp, and 1671 bp for the beta-subunit. Packaging the
alpha subunit is well within the size constraints of the AAV
genome. However, overexpression of the alpha subunit alone
would not lead to an overabundance of the missing heterodi-
meric Hex A isozyme, since the endogenous beta subunit would
become limiting in this scenario. Packaging both of these
subunits within a single AAV genome, along with the
transcriptional regulator elements necessary to drive expression,
is impractical due to size constraints. A modified beta subunit
that could form a homodimer, but function as an alpha-beta
Hex A heterodimer, such as was described by Matsuoka et al.
[12], would be of enormous value. Conceptually, such a
modified beta subunit gene could be packaged within a self-
complementary AAV vector, delivered globally to the CNS, and
supply Hex A-like activity to the majority of cells in the CNS
through cross-correction (secretion of the overexpressed homo-
dimer from infected cells, and recapture of the isozyme by
plasma membrane mannose-6-phosphate receptors on uninfect-
ed cells) [22].
Given the promising data published by Matsuoka et al. [12]
and our interest in developing gene therapy for TSD and SD
utilizing a single AAV vector, we decided to confirm and build
on their previous work. This included constructing an identical
Hex hybrid (Hex H1) and comparing its properties to a new
hybrid (Hex H2) containing additional alpha-sequences that our
active quaternary structure model [2] predicted to be involved
in GM2AP or sialic acid binding (Table 1). These hybrids were
then tested in cellulo (live cell-based) with our previously
validated, GM2AP-dependent, assay utilizing a fluorescent GM2
derivative, i.e. 2-nitro1,3-benzoxadiazol (NBD)-4-yl, covalently
attached to a short (C6) sn2 acyl chain of lyso-GM2 ganglioside
(NBD-GM2), as the substrate [23] and in vitro after ion-
exchange separation of the Hex isozymes, with and without the
Table 1. Amino acid changes mage in the H1 and H2 alpha-
beta hybrid subunits.
Wild Type beta H11 H21 Proposed Function
R312 G G GM2AP-binding
Q313 S S GM2AP-binding
N314 E E GM2AP-binding
K315 P P GM2AP-binding
L316 No Change S GM2AP-binding
D317 No Change G GM2AP-binding
T378 No Change E GM2AP-binding
D426 No Change E Sialic Acid-binding2
S427 No Change DIPV GM2AP-binding
D452 N N Sialic Acid-binding2
L453 R R Sialic Acid-binding2
1Aligned amino acids from the alpha subunit that were substituted to make the
hybrid.
2Also enhances MUGS binding and hydrolysis.
doi:10.1371/journal.pone.0057908.t001
In Cellulo Assay of Hex A Subunit-Hybrids
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addition of recombinant human His6-tagged wild-type (WT)
GM2AP (rGM2AP) [24].
Results and Discussion
Expression vectors encoding the H1 and H2 Hex hybrids were
individually transfected into both an immortalized feline SD
fibroblast line (homozygous for a 25 bp inversion at the 39 end of
the beta-coding sequence [25], an area involved in dimerization
[2]) and a human infantile TSD Glial cell line [26], and transiently
expressed to confirm that their expression would result in
increased levels of MUGS hydrolysis (Table 2). Some TSD cells
were also transfected with a vector encoding the human WT alpha
subunit as a positive control. Initial MUGS levels were clearly
above those of the untransfected (UT) cells, but were too low to
obtain conclusive results using either our in cellulo or in vitro
NBD-GM2 assays [23]. Selection of mixed colonies of perma-
nently transfected cells increased the specific activity of MUGS
hydrolysis by only 2–3 fold, which was still insufficient for the
NBD-GM2 assay. Thus, individual clonal populations of the
permanent lines were isolated, grown and assayed in order to
identify those clones that were expressing high levels of MUGS
activity (Table 3). The specific MUGS activities of ,25 clonal
lines stably expressing each construct, i.e. 125 clones, were
assessed and 12 high-expressing clonal lines selected (Table 3) for
growth and expansion. From these 12 lines a single H1 and alpha
high-expressing, clonal TSD Glial line, as well as two clonal lines
expressing H2 (at either a high or moderately high level) were
grown for in cellulo cell-feeding assays with NBD-GM2 (Table 4).
Similarly the two clonal feline SD fibroblast lines that highly
expressed either H1 or H2 were established and grown for cell-
feeding assays (Table 3 and 4). The expression of H1, H2 and
alpha was confirmed in the high-expression clonal cell lines by
Western blot analysis using a human specific rabbit IgG against
Hex A [27], which cross-reacts with both the human alpha and
beta subunits, but not the SD feline alpha subunit (Fig. 1). All of
the above data confirm that, as previously reported [6], the
substrate specificity of the beta subunit-based hybrids had indeed
been changed so that they efficiently hydrolyzed negatively
charged MUGS and potentially GM2 (Table 3). Three replicate plates of transfected (Hex H1 and H2) and UT
feline SD fibroblasts were grown in the presence of NBD-GM2
and conduritol-B-epoxide (CBE), which is an irreversible inhibitor
of glucocerebrosidase [28] and stops the degradation of NBD-
GM2 in lysosomes at the NBD derivative of glucosylceramide step.
Thus, as well as the acidic glycolipid product, NBD-GM3
ganglioside, the reaction also produces two neutral glycolipid
products, a NBD-lactosylceramide derivative and NBD-glucosyl-
ceramide [23] (Fig. 2 A & B). Cells from the 9 independent plates
were harvested and 10% of each cell suspension was removed for
MUGS and protein assays (Table 4). Enriched neutral and acidic
glycolipid fractions were prepared from the remaining 90% of
treated cells by Folch extraction, and individually analyzed by
HPTLC. Cells expressing either of the H1 or H2 hybrid clearly
were able to hydrolyze more of the NBD-GM2 than UT cells
(Fig. 2A, B, C).
Similar in cellulo assays were done with 12 independent plates
of 4 clonal populations of transfected human TSD Glial; i.e., high
expressing H1 (three replicate plates), H2 (two replicate plates),
WT alpha subunit (three replicate plates), and a moderately high
expressing H2 subunit (one plate); and three replicate plates of UT
control cells (Table 4, Fig. 3A, B, C). Surprisingly only the positive
control cells transfected with the human WT alpha cDNA
hydrolyzed significantly more NBD-GM2 than did the UT
negative control cells (Fig. 3C).
Figure 1. Western blot analysis of the lysate from wild-type
(WT) human fibroblasts (positive control), untransfected (UT)
Feline SD fibroblasts and human TSD Glial cells (negative
control), and a clonal population of the indicated cell types
highly expressing either the H1 or H2 beta-alpha hybrid
subunit (Table 1) or the WT alpha subunit. The positions of the
alpha (ap) and beta (bp) precursor polypeptides and the mature
(lysosomal) alpha (am) and beta (bm) chains are indicated. Note that
both hybrids lack the internal posttranslational cleavage site present in
the beta, but not the alpha subunit, that has been linked to GM2AP
binding.
doi:10.1371/journal.pone.0057908.g001
Table 2. Transiently Transfected Cells and Selected Mixed
Colonies.
Cells UT1 Alpha H1 H2
Human TSD Glial2 1.33 563 223 133
Feline SD Fibroblasts2 7.7 NA4 34 23
Human TSD Glial5 1.7 110 46 36
1Untransfected.
2Transiently transfected.
3Specific activity of the cell lysates, nmoles (MUGS) hr21 mg21 (total protein),
note that the specific activity of WT human fibroblast lysate is 220.
4Not Applicable.
5G418 selected mixed colonies.
doi:10.1371/journal.pone.0057908.t002
Table 3. Stably Transfected, Highly Expressing Clones from
Selected Mixed Colonies.
Cells UT1 Alpha H1 H2
Human TSD Glial 3.22
Clone-13 4212 409 270




Feline SD fibroblasts 5.1
Clone-1 NA4 272 762
1Untransfected.
2Specific activity of the cell lysates, nmoles (MUGS) hr21 mg21 (total protein).
3Highly expressing clones isolated.
4Not Applicable.
doi:10.1371/journal.pone.0057908.t003
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The most likely explanation for the different results obtained
from the SD versus the TSD cell lines is that the beta subunit-
based hybrids were able to form homodimers (which could now
hydrolyze MUGS, but could still not interact with the GM2AP-
NBD-GM2 complex) and heterodimers with the different endog-
enous Hex subunits present in the two transfected cell lines. In the
feline SD cells any hybrid heterodimer would contain an
endogenous feline alpha subunit, producing a Hex A-like isozyme
(alpha-hybrid) that may then be able to interact with the feline
GM2AP and hydrolyzed NBD-GM2. In the human TSD cells,
any hybrid heterodimer would contain an endogenous human
beta subunit, producing a Hex B-like isozymes (beta-hybrid) that
now could hydrolyze MUGS, but may still not be able to interact
with the human GM2AP-NBD-GM2 complex. To test this
hypothesis we took advantage of the facts that both hybrids
retained approximately the same neutral pI as the WT human
beta subunit and that the feline alpha-subunit has the same acidic
pI as its human counterpart. Thus hybrid homodimers could be
separated from any alpha (WT feline)-hybrid (human beta
subunit-based) heterodimers by standard DEAE ion exchange
chromatography (reviewed in [1]). At pH 6.0 and 25 mM NaCl
(10 mM phosphate buffer) Hex B (and either beta subunit-based
hybrid homodimer) does not bind to the column, Hex A (and any
feline alpha-human beta subunit-based hybrid heterodimer) is
eluted at 150 mM NaCl and Hex S at 500 mM NaCl [11]. A
stepwise elution of the ion exchange column loaded with lysates of
feline SD cells transfected with either hybrid construct, produced a
large peak of MUGS activity that did not bind to the column,
which signified the beta-subunit based hybrid homodimer.
Additionally a smaller peak of MUGS activity was eluted with
150 mM NaCl, confirming the presence of alpha-hybrid hetero-
dimers (accounting for ,25% of the cells’ MUGS activity). Finally
a very small Hex S peak was eluted with 500 mM NaCl (Fig. 4).
The two peak fractions eluted by either 25 mM or 150 mM NaCl
were individually pooled and 15 nmoles (MUGS)/hr of Hex
activity from each were assayed in vitro with NBD-GM2
contained in negatively charged liposomes, with or without added
rGM2AP [23]. As there is little additional turn-over of the NBD-
GM3 product in the in vitro assay [23] the total glycolipids were
bound to, washed and eluted (methanol) from a C-18 Zip tip,
instead of using a differential Folch extraction [29] as was done in
the in cellulo assays (above). These data confirmed that the alpha-
H1 and -H2 heterodimers, but not the H1-H1 and H2-H2
homodimers, are capable of hydrolyzing NBD-GM2 to produce
NBD-GM3, in a rGM2AP-dependent manner (Fig. 5).
Recently Matsuoka et al. reported that they had successfully
constructed a hybrid Hex subunit (H1) that as a homodimer
retained the high stability of Hex B and also was able to bind the
GM2AP-GM2 complex and hydrolyze GM2 [12]. This conclusion
was based on three experiments. The first was the demonstration
that their Hex H1 was able to hydrolyze GM2 in the presence of
2mM taurodeoxycholate. The substitution of GM2AP with this
detergent circumvents the need to form the active quaternary
structure [30], which is used in vivo. In this case the experiment
confirms that the Hex H1 is able to hydrolyze negatively charged
substrates (MUGS and GM2), but did not test the isozyme’s ability
to bind the GM2AP-GM2 complex. The second experiment
demonstrated that recombinant hybrid Hex injected intracereb-
roventricularly into SD mice was therapeutic, lowering the
amounts of stored ganglioside. One of the major problems in
translating data from mouse models of TSD and SD to humans is
the presence in mice of a metabolic bypass pathway for GM2
hydrolysis not found in humans. This pathway consists of a mouse
sialidase, which can convert GM2 to its neutral, asialo derivative
GA2 (now a potential substrate for the beta active site), coupled
with a more promiscuous mouse GM2AP, which unlike the
human GM2AP, can both weakly bind GA2 and interact with
Hex B [31]. Thus the TSD mouse is only very mildly affected as
compared to either the SD mouse [32,33] or the GM2AP-deficient
AB-variant mouse [34]. Since the mouse GM2AP can interact
with mouse (or human) Hex B [31,35], it is very likely to also be
able to interact with human Hex H1. Additionally, because Hex
H1 can hydrolyze negatively charged substrates, the need for
mouse sialidase to first convert GM2 to GA2 is eliminated, making
the mouse bypass pathway more efficient. The third experiment;
demonstrating that endogenous GM2 levels in human TSD
fibroblasts could be reduced by supplying Hex H1 in the growth
medium; is more difficult to explain. However, this conclusion was
based only on immunostaining of the cells with an anti-GM2
mouse monoclonal antibody viewed under a confocal fluorescent
microscope. Problems with this approach could relate to the
specificity and/or sensitivity of the antibody, since there are only
low levels of GM2 and the other complex gangliosides synthesized
outside of neuronal cells. Thus, while fibroblasts from GM1 or
GM2 gangliosidosis patients may contain elevated levels of GM1
or GM2, these levels remain very low and difficult to quantitate
[36–38], i.e. fibroblasts are not a storage cell-type in TSD. For this
reason, Igdoura et al. used TSD neuroglia cells to examine
changes in endogenous GM2 turnover, but when they evaluated
TSD fibroblasts they first preloaded the cells with exogenous GM2
[37]. To validate the specificity of their GM2 antibody and the
presence of stored GM2 in TSD neuroglia cells, the same group
first extracted the glycolipids from the cells and then separated
them by HPTLC. The HPTLC plate was then overlaid with their
Table 4. Cell Feeding Experiment: Total amounts of MUGS Units (nmoles/hr) and protein (mg) in each sample extracted for HPTLC
analysis.
Cell Type UT1 H1 H2 Alpha
Human TSD Glial (Units) 10 6.5 7.2 3502 2302 2002 973 5402 5402 8602 12002 10002
Human TSD Glial (mg) 2.4 1.9 1.7 0.8 0.6 0.5 1.9 1.2 1.5 0.8 1.5 0.9
Feline SD Fibroblasts (Units) 9.7 10 8.3 1802,4 2402 2302 13002,4 13002 14002 NA5 NA NA
Feline SD Fibroblasts (mg) 0.9 1.1 1.1 0.7 0.9 0.9 0.9 1.2 1.3 NA NA NA
1Untransfected.
2High expressing clone (single clone used for each of these determinations).
3Moderately high expressing clone.
4,25% of the MUGS units in these samples were found to be associated with alpha-H1 or alpha-H2 heterodimers (Fig. 4).
5Not Applicable.
doi:10.1371/journal.pone.0057908.t004
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Figure 2. In cellulo NDB-GM2 hydrolysis assays of nine
independently treated plates of three sets of Feline SD
fibroblasts. The three sets include, isolated clonal populations of
highly expressing H1 or H2 beta-alpha hybrid subunit and untrans-
fected (UT) controls. See Table 4 for total MUGS units and cell protein
contained in the cell lysates that were examined in these assays.
Loading control (LC) shows the positions of the substrate NBD-GM2,
and it break-down products; i.e, NBD-GM3, NBD derivative of GM3
ganglioside; NBD-LacCer, NBD derivative of lactosylceramide; NBD-
GlcCer, NBD derivative of glcosylceramide; NBD-Cer, NBD derivative of
ceramide (note that only low levels of NBD-Cer are seen because of the
presence of CBE in the assay, see methods). A) The HPTLC separation of
the enriched acidic glycolipid fraction (upper phase Folch extraction)
from each plate of cells. B) The HPTLC separation of the enriched
neutral glycolipid fraction (lower phase Folch extraction) from each
plate of cells. C) Stacked bar graph of the NBD-GM2 hydrolysis products
detected in A & B quantified using the Storm Imager.
doi:10.1371/journal.pone.0057908.g002
Figure 3. In cellulo NDB-GM2 assays of twelve independent
treated plates of four sets of human TSD Glial cells. These sets
include, isolated clonal populations highly expressing either the WT
alpha subunit (A), the H2 or the H1 beta-alpha hybrid subunit and
untransfected (UT) controls (see Table 4 for total MUGS units and cell
protein examined in these assays). Loading control (LC) shows the
positions of the substrate, NBD-GM2, and its break-down produces; i.e,
NBD-GM3, NBD derivative of GM3 ganglioside; NBD-LacCer, NBD
derivative of lactosylceramide; NBD-GlcCer, NBD derivative of glcosyl-
ceramide; NBD-Cer, NBD derivative of ceramide (note that only low
levels of NBD-Cer are seen because of the presence of CBE in the assay,
see methods). A) The HPTLC separation of the enriched acidic glycolipid
fraction (upper phase Folch extraction) from each plate of cells. B) The
HPTLC separation of the enriched neutral glycolipid fraction (lower
phase Folch extraction) from each plate of cells. C) Stacked bar graph of
the NBD-GM2 hydrolysis products detected in A & B (H2* indicates the
moderately high expressing clone, see Table 4) quantified using the
Storm Imager.
doi:10.1371/journal.pone.0057908.g003
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GM2 antibody and visualized in a manner similar to a Western
blot [33]. This type of experiment should always be done as a
control for the ability of GM2 antibody being used to specifically
detect stored GM2 in the TSD or SD cell-type being treated.
In conclusion, constructing a modified beta subunit that can
form a homodimer and, like heterodimeric Hex A, hydrolyze
GM2 in vivo, would be of great value in developing gene therapy
for TSD and SD utilizing a single AAV vector. While identifying
the changes to the beta active site necessary for it to efficiently bind
and hydrolyze a simple negatively charged substrate, MUGS, has
been accomplished [2,6,12], the remaining hurdle is to identify all
the alpha residues that need to be incorporated into the beta
hybrid to allow it to effectively bind the human GM2-GM2AP




The Hex alpha subunit and modified Hex beta subunits were
codon-optimized for mouse and human expression by DNA2.0
(Menlo Park, CA). The coding DNA sequences were cloned into
the pJ603 mammalian expression vector (DNA2.0), which drives
the Hex subunit expression via the CMV promoter and also co-
expresses the neomycin resistance gene. The entire alpha subunit
coding sequence was cloned into the expression construct. For the
modified beta subunits, the coding sequence beginning at the 3rd
ATG was cloned into the expression construct to minimize the size
of the coding sequence (deleting the first 25 amino acids of the
long, cleavable signal peptide), since this N-terminus was
previously shown to be dispensable [39].
Cell Lines and Tissue Culture
Immortalized fibroblast cell lines from a naturally-occurring
feline SD model (GM2 SV3) were generated by D.R. Martin [25]
by calcium phosphate transfection of primary fibroblasts with the
plasmid pSV3-DHFR (American Type Culture Collection)
containing the large T antigen of Simian Virus 40. An
immortalized human Tay-Sachs Glial cell line was obtained from
R.A. Gravel [26]. All cells were grown in alpha-minimal essential
medium from Wisent Inc. (Canada) in the presence of 1%
antibiotics (penicillin and streptomycin, Gibco BRL, Canada) and
supplemented with Fetal Bovine Serum (FBS) (Wisent Inc.,
Canada) at 10% for human cells or 1% for cat cells, and
incubated at 37uC in a humidified atmosphere with 5% CO2.
Chemicals and Hex Assays
The synthetic fluorogenic substrate, MUGS, from Toronto
Research Chemicals (Canada), was used to assay Hex A-like
activity (e.g. Hex S and the hybrids) as previously reported [40].
CBE was from Toronto Research Chemicals (Canada). Choles-
terol, purchased from Sigma-Aldrich (Canada), phosphatidyl
choline (egg) and phosphatidyl inositol (bovine liver) from Avanti
Polar Lipids (USA), and polycarbonate 100 nm filters from
Avestin, Inc. (Canada), were used to produce the previously
described [23] negatively-charged liposomes that the NBD-GM2
substrate was incorporated into for the in vitro Hex assays (see
below). Recombinant GM2AP was expressed in Escherichia coli then
purified (His6-tagged) and re-folded [24].
In cellulo NBD-GM2 assay. The fluorescent GM2 deriva-
tive, NBD-GM2, was prepared by W. Wakarchuk [23]. Confluent
transfected or non-transfected cells in 10 cm plates were grown for
18 h in FBS-free media containing NBD-GM2 (4.7 mg mL21) and
CBE (50 mM). After media removal, the cells were rinsed with PBS
and incubated with media containing 5% FBS for an additional
2 h before harvesting. The differential extraction of gangliosides
and neutral glycolipids from each cell suspension was done
according to Folch [29]. The extracts were then cleaned using C-
18 Zip Tips and prepared for glycolipid separation by HPTLC as
previously reported [40]. Bands corresponding to NBD-glycolipid
derivatives were visualized and quantified using the Storm Imager
[40].
In vitro NBD-GM2 assay. Aliquots containing 15 nmoles
(MUGS)/hr of Hex activity from the DEAE ion-exchange
separation of the Hex isozymes (see below), were incubated
overnight in McIlvaine’s citrate phosphate buffer (pH 4.1), with
NBD-GM2 incorporated into negatively-charged liposomes and
50 mM CBE plus or minus 2 mg rGM2AP, in a total reaction
Figure 4. DEAE ion-exchange separation of the Hex isozymes
from the lysate of transfected feline SD fibroblasts highly
expressing the H1 beta-alpha hybrid (similar results were
obtained using lysate from these cells expressing the H2
hybrid, thus a generic ‘‘H’’ is used for the hybrid subunit).
doi:10.1371/journal.pone.0057908.g004
Figure 5. HPTLC separation of the total glycolipid fraction from
an in vitro assay (NBD-GM2± rGM2AP) of the DEAE-separated
Hex isozymes (see Fig. 4) from lysates of transfected feline SD
fibroblasts highly expressing either the H1 or H2 beta-alpha
hybrid subunits. Lysate from normal fibroblasts, containing the same
number of MUGS units as the test samples (15 nmoles/hr), was used as
the positive control (WT). Lysate from untransfected feline SD cells,
containing the same amount of protein as the WT lysate, was used as
the negative control (UT).
doi:10.1371/journal.pone.0057908.g005
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volume of 50 mL. The glycolipids (both acidic and neutral) were
bound in a C-18 Zip tip, washed with water, eluted with 100%
methanol and concentrated by drying before their separation by
HPTLC, as previously reported [40].
Protein Analyses
Western blotting. Lysates (20 mg of total protein) from
human WT fibroblasts, feline SD fibroblasts and human TSD
Glial cells were subjected to SDS-PAGE on a 10% bis:acrylamide
gel, transferred to nitrocellulose, and processed as previously
described [27]. Blots were incubated with a rabbit polyclonal IgG
produced in our laboratory against purified human Hex A [27],
followed by a horseradish peroxidase-conjugated, goat, anti-rabbit
IgG secondary antibody, developed using chemiluminescent
substrate according to the manufacturer’s protocol (Amersham
Biosciences, UK) and recorded on BIOMAX x-ray film (Kodak)
[40].
Ion-exchange chromatography. DEAE Sepharose CL-6B
(Pharmacia), 250 mL, was pre-equilibrated in a small column
with10 mM phosphate buffer pH 6.0 containing 25 mM NaCl
and 5% glycerol. Cells from two 15 cm plates were harvested and
lysed by repeated freeze- thawing in the above 10 mM phosphate
buffer. The lysates, 500 mL, were clarified by centrifugation,
passed through individual DEAE columns and collected as the first
fraction shown in Figure 4. Each column was washed with a
further 1.5 mL, collected in 6, 250 mL fractions. Finally 1 mL of
the lysis buffer was used as a final wash and collected as a single
fraction. Only the two fractions containing the highest MUGS
activity were pooled and used to evaluate the ability of the Hex
hybrid homodimers to hydrolyze NBD-GM2 in a rGM2AP-
dependent manner in vitro. Each column was then eluted with
1.5 mL of the phosphate buffer containing 150 mM NaCl,
collected in 6, 250 mL fraction, followed by another 1 mL wash
with the same buffer. The two fractions with the highest levels of
MUGS activity were again pooled as alpha-hybrid heterodimers
and assayed in vitro with rGM2AP and NBD-GM2. Finally the
columns were eluted with 1.25 mL of buffer containing 500 mM
NaCl to collect 5, 250 mL fractions containing the alpha
homodimers, Hex S, followed by a final 1 mL wash. All the
fractions were assayed with MUGS (Fig. 4).
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